310 related articles for article (PubMed ID: 36077584)
1. Thalassemia Intermedia: Chelator or Not?
Lee YC; Yen CT; Lee YL; Chen RJ
Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077584
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Deferasirox (Exjade®) in Modulation of Iron Overload in Patients with β-Thalassemia Intermedia.
Karimi M; Arandi N; Haghpanah S; Ansari S; Azarkeyvan A; Bordbar M; Safaei S
Hemoglobin; 2015; 39(5):327-9. PubMed ID: 26114738
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
Kontoghiorghe CN; Kontoghiorghes GJ
Drug Des Devel Ther; 2016; 10():465-81. PubMed ID: 26893541
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the effects of calcium channel blockers plus iron chelation therapy versus chelation therapy only on iron overload in children and young adults with transfusion-dependent thalassemia: A randomized double-blind placebo-controlled trial.
Gupta V; Kumar I; Raj V; Aggarwal P; Agrawal V
Pediatr Blood Cancer; 2022 Jun; 69(6):e29564. PubMed ID: 35092347
[TBL] [Abstract][Full Text] [Related]
5. Iron overload in non-transfusion-dependent thalassemia: a clinical perspective.
Musallam KM; Cappellini MD; Wood JC; Taher AT
Blood Rev; 2012 Apr; 26 Suppl 1():S16-9. PubMed ID: 22631036
[TBL] [Abstract][Full Text] [Related]
6. [Current management of thalassemia intermedia].
Thuret I
Transfus Clin Biol; 2014 Nov; 21(4-5):143-9. PubMed ID: 25282488
[TBL] [Abstract][Full Text] [Related]
7. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
Daar S; Pathare AV
Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
[TBL] [Abstract][Full Text] [Related]
8. Non-Transfusion-Dependent Thalassemia: A Panoramic Review.
Shash H
Medicina (Kaunas); 2022 Oct; 58(10):. PubMed ID: 36295656
[TBL] [Abstract][Full Text] [Related]
9. Liver iron concentrations and urinary hepcidin in beta-thalassemia.
Origa R; Galanello R; Ganz T; Giagu N; Maccioni L; Faa G; Nemeth E
Haematologica; 2007 May; 92(5):583-8. PubMed ID: 17488680
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic efficacy of different iron chelators in Egyptian children with Beta Thalassemia with iron overload.
Hagag AA; Hamam MA; Taha OA; Hazaa SM
Infect Disord Drug Targets; 2015; 15(2):98-105. PubMed ID: 26205801
[TBL] [Abstract][Full Text] [Related]
11. Real-life experience with liver iron concentration R2 MRI measurement in patients with hemoglobinopathies: baseline data from LICNET.
Vitrano A; Calvaruso G; Tesé L; Gioia F; Cassarà F; Campisi S; Butera F; Commendatore V; Rizzo M; Santoro V; Cigna V; Quota A; Bagnato S; Argento C; Fidone C; Schembari D; Gerardi C; Barbiera F; Bellisssima G; Giugno G; Polizzi G; Rosso R; Abbate G; Caruso V; Chiodi E; Gamberini MR; Giorgi B; Putti MC; Filosa A; De Ritis MR; Oliva E; Arcadi N; Fustaneo M; Mistretta L; Di Maggio R; Sacco M; Veronica DS; Giangreco A; Maggio A
Eur J Haematol; 2016 Oct; 97(4):361-70. PubMed ID: 26818147
[TBL] [Abstract][Full Text] [Related]
12. Limitations of serum ferritin to predict liver iron concentration responses to deferasirox therapy in patients with transfusion-dependent thalassaemia.
Porter JB; Elalfy M; Taher A; Aydinok Y; Lee SH; Sutcharitchan P; El-Ali A; Han J; El-Beshlawy A
Eur J Haematol; 2017 Mar; 98(3):280-288. PubMed ID: 27859648
[TBL] [Abstract][Full Text] [Related]
13. Iron overload in thalassaemia intermedia: reassessment of iron chelation strategies.
Taher A; Hershko C; Cappellini MD
Br J Haematol; 2009 Dec; 147(5):634-40. PubMed ID: 19681884
[TBL] [Abstract][Full Text] [Related]
14. Iron overload in β-thalassemia intermedia: an emerging concern.
Musallam KM; Cappellini MD; Taher AT
Curr Opin Hematol; 2013 May; 20(3):187-92. PubMed ID: 23426199
[TBL] [Abstract][Full Text] [Related]
15. Iron Chelation Therapy as a Modality of Management.
Aydinok Y
Hematol Oncol Clin North Am; 2018 Apr; 32(2):261-275. PubMed ID: 29458731
[TBL] [Abstract][Full Text] [Related]
16. Non-transfusion-dependent thalassemia and thalassemia intermedia: epidemiology, complications, and management.
Vichinsky E
Curr Med Res Opin; 2016; 32(1):191-204. PubMed ID: 26479125
[TBL] [Abstract][Full Text] [Related]
17. Deferiprone versus deferoxamine in thalassemia intermedia: Results from a 5-year long-term Italian multicenter randomized clinical trial.
Calvaruso G; Vitrano A; Di Maggio R; Lai E; Colletta G; Quota A; Gerardi C; Rigoli LC; Sacco M; Pitrolo L; Maggio A
Am J Hematol; 2015 Jul; 90(7):634-8. PubMed ID: 25809173
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of deferiprone in transfusion-independent beta-thalassemia/HbE patients.
Akrawinthawong K; Chaowalit N; Chatuparisuth T; Siritanaratkul N
Hematology; 2011 Mar; 16(2):113-22. PubMed ID: 21418744
[TBL] [Abstract][Full Text] [Related]
19. Thalassemia.
Cohen AR; Galanello R; Pennell DJ; Cunningham MJ; Vichinsky E
Hematology Am Soc Hematol Educ Program; 2004; ():14-34. PubMed ID: 15561674
[TBL] [Abstract][Full Text] [Related]
20. Retinal abnormalities in β-thalassemia major.
Bhoiwala DL; Dunaief JL
Surv Ophthalmol; 2016; 61(1):33-50. PubMed ID: 26325202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
